Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (Molecular Autism, (2021), 12, 1, (38), 10.1186/s13229-021-00447-5)

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], the authors pointed out that the part of the text in Methods part was incorrectly stipulated and should read as follows: We were unable to produce or obtain SF-rich preparations for this study like those used in our previous study [6]. Based on prior testing of alternative preparations [25–27], we used commercially available crushable tablets containing broccoli seed and sprout extracts as a source of GR (equivalent to 34 μmol GR calculated to yield at least ~ 15 μmol SF) and active myrosinase enzyme. Tablets commercially produced as Avmacol® were provided by Nutramax Laboratories, Inc., Edgewood, MD. Placebo tablets, identical in size and similar in appearance to the active tablets, contained microcrystalline cellulose, red, yellow and black coloring and magnesium stearate, and were produced by Dr. Stephen Hoag, University of Maryland Department of Pharmacy.

Cite

CITATION STYLE

APA

Zimmerman, A. W., Singh, K., Connors, S. L., Liu, H., Panjwani, A. A., Lee, L. ‑C, … Fahey, J. W. (2021, December 1). Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (Molecular Autism, (2021), 12, 1, (38), 10.1186/s13229-021-00447-5). Molecular Autism. BioMed Central Ltd. https://doi.org/10.1186/s13229-021-00451-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free